• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

NIROGACESTAT Drug Record

  • Summary
  • Interactions
  • Claims
  • NIROGACESTAT chembl:CHEMBL1770916 Antineoplastic

    Alternate Names:

    PF 3084014
    PF-3084014
    PF-03084014
    NIROGACESTAT
    PF 03084014

    Drug Info:

    Drug Class Small molecule inhibitor
    (1 More Sources)

    Publications:

    Arcaroli et al., 2013, Tumours with elevated levels of the Notch and Wnt pathways exhibit efficacy to PF-03084014, a γ-secretase inhibitor, in a preclinical colorectal explant model., Br. J. Cancer
    Cui et al., 2015, Notch Pathway Inhibition Using PF-03084014, a γ-Secretase Inhibitor (GSI), Enhances the Antitumor Effect of Docetaxel in Prostate Cancer., Clin. Cancer Res.
    Wang et al., 2015, PEST domain mutations in Notch receptors comprise an oncogenic driver segment in triple-negative breast cancer sensitive to a γ-secretase inhibitor., Clin. Cancer Res.
    Papayannidis C et al., 2015, A Phase 1 study of the novel gamma-secretase inhibitor PF-03084014 in patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma., Blood Cancer J
  • NIROGACESTAT   NOTCH1

    Interaction Score: 5.09

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Approval Status Preclinical - Cell culture
    Indication/Tumor Type triple-receptor negative breast cancer
    Response Type sensitive

    PMIDs:
    23868008 26202948 25564152 26407235


    Sources:
    MyCancerGenome JAX-CKB CIViC

  • NIROGACESTAT   NOTCH2

    Interaction Score: 4.12

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    None found


    Sources:
    MyCancerGenome

  • NIROGACESTAT   NOTCH3

    Interaction Score: 4.12

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    None found


    Sources:
    MyCancerGenome

  • NIROGACESTAT   NOTCH4

    Interaction Score: 3.09

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    None found


    Sources:
    MyCancerGenome

  • NIROGACESTAT   APP

    Interaction Score: 0.4

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • MyCancerGenome: PF-03084014

    • Version: 20-Jun-2017

    Alternate Names:
    PF-03084014 Development Name

    Drug Info:
    Drug Class Small molecule inhibitor

    Publications:

  • JAX-CKB: PF-03084014

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Cui et al., 2015, Notch Pathway Inhibition Using PF-03084014, a γ-Secretase Inhibitor (GSI), Enhances the Antitumor Effect of Docetaxel in Prostate Cancer., Clin. Cancer Res.
    Wang et al., 2015, PEST domain mutations in Notch receptors comprise an oncogenic driver segment in triple-negative breast cancer sensitive to a γ-secretase inhibitor., Clin. Cancer Res.
    Arcaroli et al., 2013, Tumours with elevated levels of the Notch and Wnt pathways exhibit efficacy to PF-03084014, a γ-secretase inhibitor, in a preclinical colorectal explant model., Br. J. Cancer

  • CIViC: NIROGACESTAT

    • Version: 14-September-2020

    Alternate Names:

    Drug Info:

    Publications:
    Papayannidis C et al., 2015, A Phase 1 study of the novel gamma-secretase inhibitor PF-03084014 in patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma., Blood Cancer J

  • TTD: PF-03084014

    • Version: 2020.06.01

    Alternate Names:
    D00GPQ TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL1770916

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21